Abstract
Gabriella Macchia, Maria Antonietta Gambacorta, Carlotta Masciocchi, Giuditta Chiloiro, Giovanna Mantello, Maika di Benedetto, Marco Lupattelli, Elisa Palazzari, Liliana Belgioia, Almalina Bacigalupo, Aldo Sainato, Sabrina Montrone, Lucia Turri, Angela Caroli, Antonino De Paoli, Fabio Matrone, Carlo Capirci, Giampaolo Montesi, Rita Marina Niespolo, Mattia Falchetto Osti, Luciana Caravatta, Alessandra Galardi, Domenico Genovesi, Maria Elena Rosetto, Caterina Boso, Piera Sciacero, Lucia Giaccherini, Salvatore Parisi, Antonella Fontana, Francesco Romeo Filippone, Vincenzo Picardi, Alessio Giuseppe Morganti, Vincenzo Valentini
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Preoperative versus postoperative chemoradiotherapy for rectal cancer
10.1056/nejmoa040694 · 2004
EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum
10.1016/j.ejca.2013.06.048 · 2014
Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients
10.1016/j.ijrobp.2007.12.019 · 2008
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials
10.1200/jco.2010.33.1595 · 2011
Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96–02 randomized trial
10.1016/j.ijrobp.2011.12.002 · 2012
Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis
10.1245/s10434-011-2209-y · 2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer
10.1002/bjs.8702 · 2012
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
10.1016/s1470-2045(10)70172-8 · 2016
Effect of interval between neoadjuvant chemoradiotherapy and surgery on oncological outcome for rectal cancer: a systematic review and meta-analysis
10.1155/2016/6756859 · 2016
Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies
10.1097/sla.0000000000000368 · 2016
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921
10.1200/jco.2005.02.113 · 2005
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203
10.1200/jco.2006.06.7629 · 2006
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04
10.1200/jco.2012.42.9597 · 2012
Integration of novel agents into combined-modality treatment for rectal cancer patients
10.1007/s00066-007-9000-9 · 2007
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2
10.1200/jco.2009.25.8376 · 2010
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial
10.1200/jco.2010.34.4911 · 2011
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04
10.1200/jco.2013.53.7753 · 2014
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival at interim analysis
2014
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(15)00159-x · 2015
Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis
10.1016/j.radonc.2014.08.035 · 2014
Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy
10.1016/j.ijrobp.2012.05.017 · 2013
Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90–01 randomized trial
10.1200/jco.1999.17.8.2396 · 1999
An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer
10.1245/s10434-008-9892-3 · 2008
Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer
10.1097/sla.0b013e3181b91e63 · 2009
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
10.1002/bjs.9112 · 2013
Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection
10.1007/s10350-003-0062-1 · 2004
Regression of rectal cancer with radiotherapy with or without concurrent capecitabine – optimising the timing of surgical resection
10.1016/j.clon.2008.10.011 · 2009
Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: The key to improved tumor response and potential organ preservation
10.1016/j.jamcollsurg.2015.04.010 · 2015
Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis
10.1002/bjs.6377 · 2008
Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer
10.1016/j.amjsurg.2006.08.061 · 2006
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: A multicentre, phase 2 trial
10.1016/s1470-2045(15)00004-2 · 2015
Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: A multi-institutional study for optimal surgical timing in rectal cancer
10.1016/j.radonc.2016.03.017 · 2016
Unresolved referenced work
Kept as external metadata until matched
Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study)
10.1002/bjs.9809 · 2015
Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?
10.1016/j.ijrobp.2007.11.035 · 2008
Rectal cancer: Neoadjuvant chemoradiotherapy
10.1016/j.bpg.2016.06.004 · 2016
Timing of rectal cancer surgery following neoadjuvant chemoradiation: how close are we to striking an equipoise?
10.2217/fon-2016-0478 · 2017
Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6)
10.1200/jco.2016.67.6049 · 2016
Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?
2016
Pathologic response, when increased by longer interval, is a marker but not the cause of good prognosis in rectal cancer: 17-year follow-up of the Lyon R90–01 randomized trial
10.1016/j.ijrobp.2015.10.061 · 2016
No additional external references are available.